Cost-effectiveness of thrombolytic therapy for acute myocardial infarction

Annals of Pharmacotherapy

Volumn 31, Issue 5, 1997, Pages 596-603

  Castillo, Paul A ^a,b   Palmer, Cynthia S ^a,c   Halpern, Michael T ^c   Hatziandreu, Evi J ^d   Gersh, Bernard J ^e  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b Value Health Sciences   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d Department of Medical Statistics   (Greece)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; myocardial infarction; thrombolytics

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART REINFARCTION; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; MEDICAL FEE; META ANALYSIS; MORTALITY; PHYSICAL DISABILITY; PRIORITY JOURNAL; REVIEW; STROKE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0030974208     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100515     Document Type: Review

References (33)

1. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardio). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
2. ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous Streptokinase in acute myocar- dial infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med 1986;134:1465-71.
3. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: a preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545-9.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
5. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet 1988;2:525-30.
6. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de American del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342: 767-72.
7. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
8. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990-1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
9. Hennekens CH. Thrombolytic therapy: pre- and post-GISSI-2, ISIS-3, and GUSTO-1. Clin Cardiol 1994;17(suppl I):M5-I-17.
10. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for myocardial infarction. N Engl J Med 1995;332:1418-24.
11. Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson ANA, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
12. Laffel GL, Fineberg HV, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. JACC 1987;10:79-90.
13. Machecourt J, Dumoulin JC, Forini L, Terisse MP, Henon T, Vanzetto G, et al. Cost effectiveness of thrombolytic treatment for myocardial infarction comparison of anistreplace, alteplase and streptokinase in 270 patients treated within 4 hours. Eur Heart J 1993;14:75-83.
14. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis - a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992;13:2-8.
15. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Parker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14:108-17.
16. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993; 9:553-8.
17. Goel V, Naylor CD. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol 1992;8:31-8.
18. Herve C, Castiel D, Gaillard M, Boisvert R, Levoux V. Cost-benefit analysis of thrombolytic therapy. Eur Heart J 1990;11:1006-10.
19. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991;12:694-9.
20. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995;10:321-30.
21. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994;343:311-22.
22. Grünewald M, Seifried E. Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for acute myocardial infarction: relative efficacy of different therapeutic strategies. Fibrinolysis 1994;8:67-86.
23. 1995 Physician's GenRx, 5th ed. Riverside, CT: Denniston Publishing, Inc., 1995:57-8,1784-6.
24. Dobkin B. The economic impact of stroke. Neurology 1995;45(suppl 1):S6-S9.
25. Thorngren M, Westling B. Utilization of health care resources after stroke. A population-based study of 258 hospitalized cases followed during the first year. Acta Neurol Scand 1991;84:303-10.
26. Nicod P, Gilpin EA, Dittrich H, Hennig H, Maisel A, Blacky R, et al. Trends in the use of coronary angiography in subacute phase of myocardial infarction. Circulation 1991;84:1004-15.
27. Pryor DB, Harrell FE Jr, Rankin JS, Lee KL, Muhlbaier LH, Hlatky MA, et al. Trends in the presentation, management and survival of patients with coronary artery disease: the Duke Database for Cardiovascular Disease. In: Higgins M, Luepker RV, eds. Trends in coronary heart disease mortality: the influence of medical care. New York: Oxford University Press, 1988:76-87.
28. Centers for Disease Control and Prevention. National Hospital Discharge Survey, CD-ROM, Series 10, No. 3. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention, 1993.
29. Report of the Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med 1995;123:61-70.
30. Rose EA. Is the use of t-PA as compared with streptokinase cost effective (letter)? N Engl J Med 1995;333:1009.
31. Armentano R, Favaloro RG. Is the use of t-PA as compared with streptokinase cost effective (letter)? N Engl J Med 1995;333: 1009-10.
32. Tengs TO, Adams MA, Pliskin JS, Safran DG, Seigel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
33. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Ann Rev Public Health 1985;6:41-63.